Results 241 to 250 of about 80,637 (252)

Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity

ESMO Open, 2018
Dong-Wan Kim, Dae Seog Heo, Tae Min Kim
exaly  

Correlation between nivolumab exposure and treatment outcomes in non–small-cell lung cancer

European Journal of Cancer, 2019
R H J Mathijssen, Joachim Aerts, Stefan Sleijfer   +2 more
exaly  

Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study

Annals of Oncology, 2016
Georgina V Long, Paolo A Ascierto, Caroline Robert   +2 more
exaly  

Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143

Neuro-Oncology, 2018
David Reardon, Joachim Baehring, John Sampson   +2 more
exaly  

Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer

Lung Cancer, 2017
Jeffrey Thompson, Charu Aggarwal, Anil Vachani   +2 more
exaly  

Subcutaneous versus intravenous nivolumab for renal cell carcinoma

Annals of Oncology
José Mauricio Mota, Laurence Albiges, M Chacon   +2 more
exaly  

Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma

Cancer Medicine, 2019
Ho Yeong Lim, Jeong Il Yu, Su Jin Lee
exaly  

<p>Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients</p>

Therapeutics and Clinical Risk Management, 2019
Haijun Zhang
exaly  

Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040

Annals of Oncology
Jaclyn Neely, Bassel El-Rayes, Anthony El-Khoueiry   +2 more
exaly  

Data support longer recurrence‐free survival with nivolumab than with ipilimumab for stage III or IV melanoma

Ca-A Cancer Journal for Clinicians
exaly